Descriptive statistics of the treatment groups at baseline
. | Deferiprone . | Deferoxamine . | P . |
|---|---|---|---|
| No. randomized (%) | 29 (48) | 32 (52) | NA |
| Age, y | 25.1 ± 3.8 | 26.2 ± 4.7 | .33 |
| Sex, no. (%) | .99 | ||
| Male | 15 (52) | 16 (50) | |
| Female | 14 (48) | 16 (50) | |
| Ethnicity, no. (%) | .99 | ||
| Greek | 16 (55) | 18 (56) | |
| Italian | 13 (45) | 14 (44) | |
| Race, no. (%) | .99 | ||
| White | 29 (100) | 32 (100) | |
| Heart measures | |||
| Myocardial T2*, ms (CV %) | 13.0 (32) | 13.3 (30) | .77 |
| End-diastolic volume, mL | 134 ± 32 | 132 ± 23 | .81 |
| End-systolic volume, mL | 43 ± 14 | 41 ± 13 | .51 |
| Ejection fraction, % | 69.7 ± 5.4 | 68.4 ± 4.9 | .34 |
| Iron measures | |||
| Liver iron concentration, μg/L | 6.16 ± 6.0 | 6.32 ± 5.8 | .92 |
| Serum ferritin level, μg/L | 1791 ± 1029 | 2795 ± 2441 | .039 |
| No. with serum ferritin levels above 2500 μg/L (%) | 5 (17) | 13 (41) | .055 |
| Blood measures | |||
| Transfusional iron input, mL/kg/year | 152 ± 43.4 | 144 ± 44.4 | .52 |
| Hemoglobin level, g/L | 105 ± 12.0 | 113 ± 11.9 | .023 |
| Total white blood cell count, × 109/L | 7.86 ± 3.39 | 11.5 ± 9.42 | .047 |
| Corrected white blood cell count, × 109/L | 7.68 ± 2.96 | 9.79 ± 4.49 | .033 |
| Absolute neutrophil count, × 109/L | 4.26 ± 1.62 | 5.10 ± 2.28 | .11 |
| Platelet count, × 109/L | 318 ± 129 | 318 ± 159 | .99 |
| Liver measure | |||
| Alanine transaminase, U/L | 37.7 ± 32.1 | 52.2 ± 33.8 | .093 |
| Hepatitis C-positive, no. (%) | .44 | ||
| Yes | 18 (62) | 16 (50) | |
| No | 11 (38) | 16 (50) | |
| HIV-positive, no. (%) | NA | ||
| Yes | 0 (0) | 0 (0) | |
| No | 29 (100) | 32 (100) | |
| Splenectomy, no. (%) | .079 | ||
| Yes | 4 (14) | 11 (34) | |
| No | 25 (86) | 21 (66) | |
| Other biochemistry | |||
| Creatinine level, μM | 71.0 ± 12.5 | 69.1 ± 12.8 | .56 |
| Zinc level, μM | 13.0 ± 3.6 | 13.3 ± 2.3 | .78 |
| Weight, kg | 57.7 ± 7.9 | 60.6 ± 13.2 | .30 |
. | Deferiprone . | Deferoxamine . | P . |
|---|---|---|---|
| No. randomized (%) | 29 (48) | 32 (52) | NA |
| Age, y | 25.1 ± 3.8 | 26.2 ± 4.7 | .33 |
| Sex, no. (%) | .99 | ||
| Male | 15 (52) | 16 (50) | |
| Female | 14 (48) | 16 (50) | |
| Ethnicity, no. (%) | .99 | ||
| Greek | 16 (55) | 18 (56) | |
| Italian | 13 (45) | 14 (44) | |
| Race, no. (%) | .99 | ||
| White | 29 (100) | 32 (100) | |
| Heart measures | |||
| Myocardial T2*, ms (CV %) | 13.0 (32) | 13.3 (30) | .77 |
| End-diastolic volume, mL | 134 ± 32 | 132 ± 23 | .81 |
| End-systolic volume, mL | 43 ± 14 | 41 ± 13 | .51 |
| Ejection fraction, % | 69.7 ± 5.4 | 68.4 ± 4.9 | .34 |
| Iron measures | |||
| Liver iron concentration, μg/L | 6.16 ± 6.0 | 6.32 ± 5.8 | .92 |
| Serum ferritin level, μg/L | 1791 ± 1029 | 2795 ± 2441 | .039 |
| No. with serum ferritin levels above 2500 μg/L (%) | 5 (17) | 13 (41) | .055 |
| Blood measures | |||
| Transfusional iron input, mL/kg/year | 152 ± 43.4 | 144 ± 44.4 | .52 |
| Hemoglobin level, g/L | 105 ± 12.0 | 113 ± 11.9 | .023 |
| Total white blood cell count, × 109/L | 7.86 ± 3.39 | 11.5 ± 9.42 | .047 |
| Corrected white blood cell count, × 109/L | 7.68 ± 2.96 | 9.79 ± 4.49 | .033 |
| Absolute neutrophil count, × 109/L | 4.26 ± 1.62 | 5.10 ± 2.28 | .11 |
| Platelet count, × 109/L | 318 ± 129 | 318 ± 159 | .99 |
| Liver measure | |||
| Alanine transaminase, U/L | 37.7 ± 32.1 | 52.2 ± 33.8 | .093 |
| Hepatitis C-positive, no. (%) | .44 | ||
| Yes | 18 (62) | 16 (50) | |
| No | 11 (38) | 16 (50) | |
| HIV-positive, no. (%) | NA | ||
| Yes | 0 (0) | 0 (0) | |
| No | 29 (100) | 32 (100) | |
| Splenectomy, no. (%) | .079 | ||
| Yes | 4 (14) | 11 (34) | |
| No | 25 (86) | 21 (66) | |
| Other biochemistry | |||
| Creatinine level, μM | 71.0 ± 12.5 | 69.1 ± 12.8 | .56 |
| Zinc level, μM | 13.0 ± 3.6 | 13.3 ± 2.3 | .78 |
| Weight, kg | 57.7 ± 7.9 | 60.6 ± 13.2 | .30 |
Data are shown as number (%) or mean ± SD, except for the myocardial T2*, which is shown as geometric mean and coefficient of variation (CV).
NA indicates not applicable.